Abstract
The HOPE TIPS study assessed the practicality and tolerability of ramipril titration to a target dose of 10 mg (as achieved in definitive efficacy studies) in a clinical practice setting. 3881 patients at high cardiovascular risk (HOPE study criteria) were recruited in primary and specialist care settings in 9 countries by 439 investigators. Dose titration of ramipril from 2.5 mg to 10 mg daily took place over 9–12 weeks. The mean age of the patients was 64 years, 60% were male and 79% Asian. The target dosage of 10 mg daily was reached in 73% of patients with 96% of patients achieving 5 mg or 10 mg daily. During the study period uncontrolled hypertension (> 160/90) was recorded in 15% of patients, myocardial infarction or unstable angina 1.6%, heart failure 0.4%, new diabetes 0.6%. Only 9.8% of patients discontinued treatment with 5.9% attributed to treatment side-effects and 4% related to cough. The large majority of patients in a wide range of clinical practice settings with high cardiovascular risk can be treated with ramipril titrated to 10 mg daily with good tolerability.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Murray CJL, Lopez AD, eds. The global burden of disease: A comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Boston: Harvard School of Public Health, 1996.
Yusuf S, Hawken S, Ôunpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet 2004;364:937–953.
Third Joint Task Force of the European and other Societies. European guidelines on cardiovascular disease prevention in clinical practice. New Euro J CV Prev and Rehab 2003;10(Suppl 1):S11–S78.
New Zealand Guidelines Group. The Assessment and Management of Cardiovascular Risk. December 2003.
Heart Outcomes Prevention Evaluation (HOPE) study investigators. Effects of an angiotensin converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145–153.
Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary heart disease: Randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782–788.
The PEACE Trial Investigators. Angiotensin converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351:2058–2068.
Antithrombotic Trialists’ Collaboration, Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. BMJ 2002;324:71–86.
Yusuf S, Peto R, Lewis J, et al. Beta-blockade during and after myocardial infarction: An overview of the randomised trials. Prog Cardiovasc Dis 1985;27:335–371.
Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: The Scandinavian Simvastatin Survival (4S) Study. Lancet 1994;334:1383–1389.
Yusuf S, Clinical, public health and research implications of the Heart Outcomes Prevention Evaluation (HOPE) study. Eur Heart J 2001;22:103–104.
Sharpe N. Matching the standards of clinical trial evidence with application in practice. Int J Clin Pract 2002;56:772–775.
Kaplan NM. The CARE study, a postmarketing evaluation of ramipril in 11,100 patients. Clin Ther 1996;18:658–670.
Author information
Authors and Affiliations
Corresponding author
Additional information
on behalf of the international HOPE TIPS investigators
Rights and permissions
About this article
Cite this article
Sharpe, N. The HOPE TIPS: The HOPE Study Translated into Practices. Cardiovasc Drugs Ther 19, 197–201 (2005). https://doi.org/10.1007/s10557-005-1375-1
Issue Date:
DOI: https://doi.org/10.1007/s10557-005-1375-1